血清HBV RNA的临床研究进展

摘要/Abstract

摘要： 慢性乙型肝炎病毒(hepatitis B virus,HBV)感染可导致诸多肝脏问题,共价闭合环状DNA(covalently closed circular DNA,cccDNA)的存在是造成HBV持续感染、难以清除的主要原因。cccDNA检测依赖于肝活检,限制了其临床广泛应用,而HBV感染者血清中的HBV RNA主要为前基因组RNA(pregenomic RNA,pgRNA),由cccDNA转录产生,可以反映cccDNA的转录活性,在评估抗病毒治疗效果以及预测停药后复发风险等方面具有较好的指示性,故本文就血清HBV RNA的相关临床研究进展作一综述。

陈芬兰, 程计林, 林文, 陈丽萍. 血清HBV RNA的临床研究进展[J]. 肝脏, 2023, 28(5): 607-610.

参考文献

[1] Wang ML, Liao J, Ye F, et al. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol, 2021, 93(6): 3688-3696.
[2] 鲁凤民, 王杰, 庄辉. HBV RNA病毒样颗粒的潜在临床意义. 中华肝脏病杂志, 2016, 24(9): 641-642.
[3] 张琪. 血清HBV RNA在抗病毒治疗中的应用进展. 重庆医学, 2022, 51(5): 890-894.
[4] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 肝脏, 2019, 24(12): 1335-1356.
[5] Wu Y, Wen J, Xiao W, et al. Pregenomic RNA: How to assist the management of chronic hepatitis B?.Rev Med Virol,2019, 29(4) :e2051.
[6] 陈靖赜, 祁玮, 胡明乐,等. HBV前基因组RNA水平与慢性乙型肝炎患者停药后复发风险的相关性. 肝脏,2022, 27(4): 413-417,425.
[7] Shen S,Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog, 2020, 16(10): e1008945.
[8] Gu Y, Chen L, Lian Y, et al. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naive chronic hepatitis B patients. J Med Virol, 2020, 92(3): 317-328.
[9] Butler EK, Gersch J, Mcnamara A, et al. Hepatitis B virus serum dna and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology, 2018, 68(6): 2106-2117.
[10] Chan HLY, Chan FWS, HUI AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat, 2019, 26(1): 126-135.
[11] Huang YW, Takahashi S, Tsuge M, et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther, 2015, 20(4): 369-375.
[12] Ghany MG, King WC, Lisker-Melman M, et al. Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology, 2021, 74(5): 2395-2409.
[13] Carey I, Gersch J, Wang B, et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy. Hepatology, 2020, 72(1): 42-57.
[14] Wang X, Wang Z, Chi X, et al. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. Int J Infect Dis,99: 171-178.
[15] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol,2016, 65(4): 700-710.
[16] Mak LY, Cloherty G, Wong DK, et al. HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology, 2021, 73(6): 2167-2179.
[17] Goncalves A, Lemenuel-Diot A, Cosson V, et al. What drives the dynamics of HBV RNA during treatment?. J Viral Hepat, 2021, 28(2): 383-392.
[18] LUO H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat, 2020, 27(3): 323-328.
[19] Van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61(1): 66-76.
[20] Luo H, Zhang XX, Cao LH, et al. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World Journal of Gastroenterology, 2019, 25(6): 719-728.
[21] 朱莹, 杨可立, 李锋,等. 血清HBV pgRNA在慢性乙型肝炎患者聚乙二醇化干扰素抗病毒过程中的临床价值.国际医药卫生导报,2019, 25(13): 2046-2049,2081.
[22] Jia W, Zhu MQ, Qi X, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J, 2019, 16(1):61.
[23] Huang H, Wang J, Li W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol, 2018, 99-100: 71-78.
[24] Chen YC, Jeng WJ, Chu CM, et al. Decreasing levels of hbsag predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol, 2012, 10(3): 297-302.
[25] Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 2021, 70(4): 775-783.
[26] Yang L, Ye S, Zhao X, et al. Molecular characterization of HBV DNA integration in patients with hepatitis and hepatocellular carcinoma. J Cancer, 2018, 9(18): 3225-3235.
[27] Lindh M, Rydell GE, Larsson SB. Impact of integrated viral DNA on the goal to clear hepatitis B surface antigen with different therapeutic strategies. Curr Opin Virol, 2018, 30: 24-31.
[28] Wu W, Wu D, Yan W, et al. Interferon-induced macrophage-derived exosomes mediate antiviral activity against hepatitis B virus through miR-574-5p. J Infect Dis, 2021, 223(4): 686-698.
[29] Bloom K, Maepa MB, Ely A, et al. Gene therapy for chronic HBV-Can we eliminate cccDNA?. Genes, 2018, 9(4),207.
[30] Yang L, Shi LP, Chen HJ, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin, 2014, 35(3): 410-418.
[31] Yuen MF, Schiefke I, Yoon JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection. Hepatology, 2020, 72(1): 19-31.